Hepatitis B Reactivation in Patients with Hematological Malignancies and Stem Cell Transplantation

Reddy, B. Narasimha

doi:10.4172/2165-7831.1000114

J Blood Lymph

2014

DOI: 10.4172/2165-7831.1000114

|View full text |Cite

Hepatitis B Reactivation in Patients with Hematological Malignancies and Stem Cell Transplantation

B. Narasimha Reddy¹

Abstract: Hepatitis B infection is the leading cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma and is thought to be responsible for million deaths per year globally. Management of patients with resolved or active hepatitis B and cancer is a challenge and these patients are at higher risk of hepatitis B related complications due to immunosuppression and loss of prior immunity. The treating hematologist needs to understand the biology of this common virus, its potential for long-term harm, the necessary… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2021

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Application and Reliability of Caprini Thrombus Risk Assessment Scale in Risk Assessment of Venous Thromboembolism in Acute and Severe Uygur Patients

Yue¹,

Zuo²,

Si³

et al. 2019

IJCM

View full text Add to dashboard Cite

Background: To explore the application and reliability of Caprini thromboembolism risk assessment scale in the risk assessment of venous thromboembolism in acute and severe uygur patients. Methods: 160 cases of acute and severe Uighur patients with venous thrombo embolism (VTE) that were treated in our hospital from December 2017 to December 2018 were selected as the research group. 160 cases of acute and severe uygur patients without VTE admitted to our hospital in the same period were selected as the control group. Caprini thrombus risk assessment scale and Padua thrombus risk assessment scale were used to evaluate in both groups. The general data of the two groups were compared. The results of the two groups were consistent using Caprini and Padua blood clot risk assessment scales. Clinical efficacy of two different thrombosis risk assessment scales in risk assessment of VTE. Results: Group and control group in the gender distribution, backlog of red blood cells and platelet count have no significant difference (P > 0.05), the team average age, average hospitalization days were significantly less than control group (P < 0.05), the team hemoglobin level was significantly higher than that of control group (P < 0.05), the team of white blood cells were significantly lower than control group (P < 0.05). Caprini thrombosis score was used to evaluate 156 high-risk patients and 164 low-risk patients. A total of 75 cases of high-risk patients and 245 cases of low-risk patients were assessed by Padua thrombosis score, and the results of the two assessment methods were significantly different (X 2 = 6.956, P < 0.05). Consistency (Kappa coefficient) was 0.58, indicating medium consistency. The specificity of Caprini thrombus score was significantly lower than that of Padua thrombus score (P < 0.05), the sensitivity and negative predictive value of Caprini thrombus score were significantly higher than that of Padua thrombus score (P < 0.05), and there was no significant difference in the positive predictive value between the two groups (P > 0.05). Conclusion: The sensitivity, negative predictive value and positive predictive value of Caprini thrombosis risk assessment scale in VTE risk assessment of acute and severe uygur patients are very prominent, and the clinical efficacy is better, which is worthy of application.

show abstract

Application and Reliability of Caprini Thrombus Risk Assessment Scale in Risk Assessment of Venous Thromboembolism in Acute and Severe Uygur Patients

Yue¹,

Zuo²,

Si³

et al. 2019

IJCM

View full text Add to dashboard Cite

show abstract

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

et al. 2017

View full text Add to dashboard Cite

show abstract

Evaluation of the Renal Safety of Direct Acting Antivirals in Chronic Hepatitis C Patients

Ashram¹,

Saleh

2021

JAMPS

View full text Add to dashboard Cite

Objective:Direct acting antivirals (DAA) is a class of antivirals that hasbeen extensively used in chronic hepatitis C virus (HCV) patients over the past 6 years.Despite the excellent therapeutic benefits of DAA, there is a knowledge gap regardingthe safety of this class. Several reports of possible renal toxicity associated with DAAadministration can be found in the literature. The aims of this study are: to assess therenal safety of DAA used for the treatment of chronic HCV infection and to quantify the odds ofdeveloping renaltoxicityin patients withchronicHCV viralinfection. Study Design: Disproportionalityanalysiswasusedtodetectsignalsofpotentialsideeffects. Place andDuration: Amman –Jordan,One year study since September 2017 to march 2018. Methods: The method that was applied in the current study is obtaining the data from United States (US) food and drug administration(FDA)adverseeventreportingsystem(FAERS).DatabetweenJuly,2014andSeptember,2017werecombinedandexplored.Disproportionalityanalysiswasconducted to reports from chronic HCV patients to explore possible association betweenDAA administrationand renalsideeffects. Results: This study showed that a total of 3,837,418 safety reports were available in the period between July,2014 and September, 2017. Patients with chronic HCV infection represent 22,022 cases.When considering all DAA as drug of interest, the use of DAA alone or in combinationwith interferon and/or ribavirin did not increase the risk of having renal side effects.Exploring individual DAA demonstrated a significant association between the incidenceofrenalsideeffectsandtheadministrationoftelapreviranddasabuvir.ConsideringrenalsideeffectsindividuallyshowedasignificantassociationbetweenDAAadministrationand chronickidney disease. Conclusions: In this study, we reported a significant association between DAA administration andchronic kidney disease and between telaprevir or dasabuvir and renal side effect. Thesefindings are used for hypothesis generation rather than testing.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Hepatitis B Reactivation in Patients with Hematological Malignancies and Stem Cell Transplantation

Cited by 3 publications

References 34 publications

Application and Reliability of Caprini Thrombus Risk Assessment Scale in Risk Assessment of Venous Thromboembolism in Acute and Severe Uygur Patients

Application and Reliability of Caprini Thrombus Risk Assessment Scale in Risk Assessment of Venous Thromboembolism in Acute and Severe Uygur Patients

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Evaluation of the Renal Safety of Direct Acting Antivirals in Chronic Hepatitis C Patients

Contact Info

Product

Resources

About